Erythropoietin (EPO) is a circulating hormone conventionally considered to be responsible
for erythropoiesis. In addition to facilitating red blood cell production, EPO has pluripotent …

Glaucoma can cause irreversible vision loss and is the second leading cause of blindness
worldwide. The disease mechanism is complex and various factors have been implicated in …

Erythropoietin (EPO) is known as a hormone for erythropoiesis in response to anemia and
hypoxia. However, the effect of EPO is not only limited to hematopoietic tissue. Several …

Erythropoietin (EPO) is a glycoprotein hormone conventionally thought to be responsible
only in producing red blood cells in our body. However, with the discovery of the presence of …

Aims Recent studies have showed that erythropoietin (EPO) is a neuroprotectant for central
nerve system neurons in addition to being a hematopoietic cytokine in response to hypoxia …

Erythropoietin (EPO) is a glycoprotein hormone that regulates hematopoiesis in the human
body. The presence of EPO and its receptors in different tissues indicates that this hormone …

Glaucoma is a progressive optic neuropathy that is the leading cause of irreversible
blindness in the world. Although methods to lower intraocular pressure are the mainstay of …

Erythropoietin (EPO) is neuroprotective in multiple models of neurodegenerative diseases,
including glaucoma. EPO-R76E retains the neuroprotective effects of EPO but diminishes …

purpose. Retinal ganglion cell (RGC) loss occurs in response to increased intraocular
pressure (IOP) and/or retinal ischemia in glaucoma and leads to impairment of vision. This …

Purpose To review the current literature on ocular application of erythropoietin (EPO).
Methods A comprehensive search was performed on Pubmed and Scopus databases. All …